person · Reporting owner

Molineaux Christopher P.

Disclosed activity across 1 company

Tapewire entity: 40388
SEC CIK: 0001654773

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 04, 2026	June 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	69,536	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 69,536 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03	Direct	42,350	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,987	Reported balance After 2026-06-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

F5: The shares underlying these restricted stock units vested on June 5, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001654773-26-000003 · form4-06082026_040610.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	11,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001654773-26-000003 · form4-06082026_040610.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	10,987	$0.00	$0.00	Disclosure SEC source: 0001654773-26-000003 · form4-06082026_040610.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $4.71	$0.00	Disclosure SEC source: 0001654773-26-000003 · form4-06082026_040610.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016247 · form4-06092025_040601.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,793	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-016247 · form4-06092025_040601.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016247 · form4-06092025_040601.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001415889-25-016247 · form4-06092025_040601.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016194 · form4-06102024_040607.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001415889-24-016194 · form4-06102024_040607.xml · derivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015366 · form4-06042024_040614.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015366 · form4-06042024_040614.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:32 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock Option (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-23-039080 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested in twelve equal monthly installments commencing July 4, 2020, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:32 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	16,500	$1.41	$23,265.00	Disclosure SEC source: 0001209191-23-039080 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock Option (right to buy) · Derivative	198	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0001209191-23-038409 · doc4.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 198 shares Expires 2024-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock Option (right to buy) · Derivative	51	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001209191-23-038409 · doc4.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	198	$1.52	$300.96	Disclosure SEC source: 0001209191-23-038409 · doc4.xml · nonDerivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2023 Filed Jun 20, 2023 20:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	51	$0.72	$36.72	Disclosure SEC source: 0001209191-23-038409 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034455 · doc4.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034455 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034455 · doc4.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034455 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034596 · doc4.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034596 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034596 · doc4.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034596 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document
June 03, 2021 Filed Jun 5, 2021 00:05 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038452 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document
June 03, 2021 Filed Jun 5, 2021 00:05 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001209191-21-038452 · doc4.xml · derivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document
June 06, 2020 Filed Jun 8, 2020 21:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035034 · doc4.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F4 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document
June 06, 2020 Filed Jun 8, 2020 21:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	7,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-035034 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2020 Filed Jun 8, 2020 21:31 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantOption Grant (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-20-035034 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:26 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016084 · doc4.xml · derivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:26 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016084 · doc4.xml · derivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:26 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	8,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-016084 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 06, 2019 Filed Jun 10, 2019 20:52 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035835 · doc4.xml · derivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. Read SEC document
June 07, 2018 Filed Jun 8, 2018 20:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $18.35	$0.00	Disclosure SEC source: 0001209191-18-036651 · doc4.xml · derivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document
April 06, 2018 Filed Apr 9, 2018 20:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	SaleCommon Stock	2,300	$16.52	$37,996.00	Disclosure SEC source: 0001209191-18-024355 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,682 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 20, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.24 to $16.88, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	264	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · derivative · entry 6 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198 Underlying: Common Stock · 264 shares Expires 2024-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	120	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · derivative · entry 5 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51 Underlying: Common Stock · 120 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	1,993	$0.00 Strike: $0.41	$0.00	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,993 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this option vested on January 29, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	264	$1.52	$401.28	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · nonDerivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	120	$0.72	$86.40	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · nonDerivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 20, 2018 Filed Mar 22, 2018 20:35 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	1,993	$0.41	$817.13	Disclosure SEC source: 0001209191-18-021261 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2017 Filed Jun 16, 2017 23:44 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $24.58	$0.00	Disclosure SEC source: 0001209191-17-040671 · doc4.xml · derivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	311	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · derivative · entry 6 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171 Underlying: Common Stock · 311 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	592	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · derivative · entry 5 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462 Underlying: Common Stock · 592 shares Expires 2024-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionStock option (right to buy) · Derivative	6,702	$0.00 Strike: $0.41	$0.00	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · derivative · entry 4 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,993 Underlying: Common Stock · 6,702 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying this option vested on January 29, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	311	$0.72	$223.92	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · nonDerivative · entry 3 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	592	$1.52	$899.84	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · nonDerivative · entry 2 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 17, 2017 Filed Mar 22, 2017 00:43 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	6,702	$0.41	$2,747.82	Disclosure SEC source: 0001209191-17-022143 · doc4.xml · nonDerivative · entry 1 Molineaux Christopher P. · CIK 0001654773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.